-
市场
-
产品
-
资讯
-
Moo社区
-
课堂
-
查看更多
-
功能介绍
-
费用费用透明，无最低余额限制
投资选择、功能介绍、费用相关信息由Moomoo Financial Inc.提供
- English
- 中文繁體
- 中文简体
- 深色
- 浅色
MiNK Therapeutics (NASDAQ:INKT) Stock Price Down 0.4%
MiNK Therapeutics (NASDAQ:INKT) Stock Price Down 0.4%
MiNK Therapeutics, Inc. (NASDAQ:INKT – Get Rating) shares traded down 0.4% during mid-day trading on Wednesday . The stock traded as low as $2.50 and last traded at $2.51. 7,858 shares changed hands during mid-day trading, a decline of 95% from the average session volume of 169,116 shares. The stock had previously closed at $2.52.
MiNK Therapeutics Price Performance
The company's 50-day moving average is $2.35 and its 200-day moving average is $2.02.
Get MiNK Therapeutics alerts:MiNK Therapeutics (NASDAQ:INKT – Get Rating) last announced its quarterly earnings results on Thursday, November 3rd. The company reported ($0.19) earnings per share (EPS) for the quarter, beating the consensus estimate of ($0.23) by $0.04. Analysts anticipate that MiNK Therapeutics, Inc. will post -0.84 EPS for the current fiscal year.
Institutional Investors Weigh In On MiNK Therapeutics
An institutional investor recently bought a new position in MiNK Therapeutics stock. First Republic Investment Management Inc. acquired a new position in shares of MiNK Therapeutics, Inc. (NASDAQ:INKT – Get Rating) in the 3rd quarter, according to its most recent filing with the Securities and Exchange Commission (SEC). The institutional investor acquired 81,500 shares of the company's stock, valued at approximately $172,000. First Republic Investment Management Inc. owned approximately 0.24% of MiNK Therapeutics at the end of the most recent reporting period. Institutional investors own 1.07% of the company's stock.MiNK Therapeutics Company Profile
(Get Rating)
MiNK Therapeutics, Inc, a clinical stage biopharmaceutical company, engages in the discovery, development, and commercialization of allogeneic, off-the-shelf, invariant natural killer T (iNKT) cell therapies to treat cancer and other immune-mediated diseases. Its product candidate is AGENT-797, an off-the-shelf, allogeneic for iNKT cell therapy and treatment of various myeloma diseases, which is in Phase 1 clinical trials.
Featured Articles
- Get a free copy of the StockNews.com research report on MiNK Therapeutics (INKT)
- There Is Fundamental Value In Broadcom, And It Yields 3.35%
- Costco vs Amazon: an end of the year showdown
- Discount Retailers Could Make Good Bargain Stocks
- Can Pfizer, Johnson & Johnson Continue Outperforming the Index?
- This Is Why Daktronics Fell 40% In One Day
Receive News & Ratings for MiNK Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for MiNK Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.
MiNK Therapeutics, Inc. (NASDAQ:INKT – Get Rating) shares traded down 0.4% during mid-day trading on Wednesday . The stock traded as low as $2.50 and last traded at $2.51. 7,858 shares changed hands during mid-day trading, a decline of 95% from the average session volume of 169,116 shares. The stock had previously closed at $2.52.
明克治疗公司(纳斯达克代码：iNKT-GET Rating)股价周三午盘下跌0.4%。该股交易价格低至2.50美元，最后报2.51美元。午盘交易中，有7,858股股票易手，较169,116股的平均成交量下降了95%。该股此前收盘价为2.52美元。
MiNK Therapeutics Price Performance
水貂治疗公司的价格表现
The company's 50-day moving average is $2.35 and its 200-day moving average is $2.02.
该公司50日移动均线切入位在2.35美元，200日移动均线切入位在2.02美元。
MiNK Therapeutics (NASDAQ:INKT – Get Rating) last announced its quarterly earnings results on Thursday, November 3rd. The company reported ($0.19) earnings per share (EPS) for the quarter, beating the consensus estimate of ($0.23) by $0.04. Analysts anticipate that MiNK Therapeutics, Inc. will post -0.84 EPS for the current fiscal year.
貂皮治疗公司(纳斯达克代码：iNKT-GET Rating)上一次公布季度收益是在11月3日星期四。该公司公布了该季度每股收益(EPS)(0.19美元)，比普遍预期的(0.23美元)高0.04美元。分析师预计，水貂治疗公司本财年的每股收益将达到0.84美元。
Institutional Investors Weigh In On MiNK Therapeutics
机构投资者看好水貂治疗公司
MiNK Therapeutics Company Profile
水貂治疗公司简介
(Get Rating)
(获取评级)
MiNK Therapeutics, Inc, a clinical stage biopharmaceutical company, engages in the discovery, development, and commercialization of allogeneic, off-the-shelf, invariant natural killer T (iNKT) cell therapies to treat cancer and other immune-mediated diseases. Its product candidate is AGENT-797, an off-the-shelf, allogeneic for iNKT cell therapy and treatment of various myeloma diseases, which is in Phase 1 clinical trials.
明克治疗公司是一家临床阶段的生物制药公司，致力于同种异体、现成、不变的自然杀伤T(INKT)细胞疗法的发现、开发和商业化，以治疗癌症和其他免疫介导性疾病。它的候选产品是AGENT-797，这是一种现成的同种异体药物，用于iNKT细胞治疗和治疗各种骨髓瘤疾病，目前处于第一阶段临床试验。
Featured Articles
专题文章
- Get a free copy of the StockNews.com research report on MiNK Therapeutics (INKT)
- There Is Fundamental Value In Broadcom, And It Yields 3.35%
- Costco vs Amazon: an end of the year showdown
- Discount Retailers Could Make Good Bargain Stocks
- Can Pfizer, Johnson & Johnson Continue Outperforming the Index?
- This Is Why Daktronics Fell 40% In One Day
- 免费获取StockNews.com关于水貂治疗的研究报告(INKT)
- 博通有基本面价值，收益率为3.35%
- 好市多VS亚马逊：年底摊牌
- 折扣零售商可以做好的便宜货
- 辉瑞、强生能否继续跑赢该指数？
- 这就是为什么达科电子在一天内下跌了40%
Receive News & Ratings for MiNK Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for MiNK Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.
接受水貂治疗日报的新闻和评级-在下面输入您的电子邮件地址，通过MarketBeat.com的免费每日电子邮件时事通讯接收对水貂治疗和相关公司的最新新闻和分析师评级的每日简要摘要。
moomoo是Moomoo Technologies Inc.公司提供的金融信息和交易应用程序。
在美国，moomoo上的投资产品和服务由Moomoo Financial Inc.提供，一家受美国证券交易委员会（SEC）监管的持牌主体。 Moomoo Financial Inc.是金融业监管局（FINRA）和证券投资者保护公司（SIPC）的成员。
在新加坡，moomoo上的投资产品和服务是通过Moomoo Financial Singapore Pte. Ltd.提供，该公司受新加坡金融管理局（MAS）监管(牌照号码︰CMS101000) ，持有资本市场服务牌照 (CMS) ，持有财务顾问豁免（Exempt Financial Adviser）资质。本内容未经新加坡金融管理局的审查。
在澳大利亚，moomoo上的金融产品和服务是通过Futu Securities (Australia) Ltd提供，该公司是受澳大利亚证券和投资委员会(ASIC)监管的澳大利亚金融服务许可机构（AFSL No. 224663）。请阅读并理解我们的《金融服务指南》、《条款与条件》、《隐私政策》和其他披露文件，这些文件可在我们的网站 https://www.moomoo.com/au中获取。
在加拿大，通过moomoo应用提供的仅限订单执行的券商服务由Moomoo Financial Canada Inc.提供，并受加拿大投资监管机构（CIRO）监管。
在马来西亚，moomoo上的投资产品和服务是通过Moomoo Securities Malaysia Sdn. Bhd. 提供，该公司受马来西亚证券监督委员会（SC）监管(牌照号码︰eCMSL/A0397/2024) ，持有资本市场服务牌照 (CMSL) 。本内容未经马来西亚证券监督委员会的审查。
Moomoo Technologies Inc., Moomoo Financial Inc., Moomoo Financial Singapore Pte. Ltd., Futu Securities (Australia) Ltd, Moomoo Financial Canada Inc.,和Moomoo Securities Malaysia Sdn. Bhd.是关联公司。
风险及免责提示
moomoo是Moomoo Technologies Inc.公司提供的金融信息和交易应用程序。
在美国，moomoo上的投资产品和服务由Moomoo Financial Inc.提供，一家受美国证券交易委员会（SEC）监管的持牌主体。 Moomoo Financial Inc.是金融业监管局（FINRA）和证券投资者保护公司（SIPC）的成员。
在新加坡，moomoo上的投资产品和服务是通过Moomoo Financial Singapore Pte. Ltd.提供，该公司受新加坡金融管理局（MAS）监管(牌照号码︰CMS101000) ，持有资本市场服务牌照 (CMS) ，持有财务顾问豁免（Exempt Financial Adviser）资质。本内容未经新加坡金融管理局的审查。
在澳大利亚，moomoo上的金融产品和服务是通过Futu Securities (Australia) Ltd提供，该公司是受澳大利亚证券和投资委员会(ASIC)监管的澳大利亚金融服务许可机构（AFSL No. 224663）。请阅读并理解我们的《金融服务指南》、《条款与条件》、《隐私政策》和其他披露文件，这些文件可在我们的网站 https://www.moomoo.com/au中获取。
在加拿大，通过moomoo应用提供的仅限订单执行的券商服务由Moomoo Financial Canada Inc.提供，并受加拿大投资监管机构（CIRO）监管。
在马来西亚，moomoo上的投资产品和服务是通过Moomoo Securities Malaysia Sdn. Bhd. 提供，该公司受马来西亚证券监督委员会（SC）监管(牌照号码︰eCMSL/A0397/2024) ，持有资本市场服务牌照 (CMSL) 。本内容未经马来西亚证券监督委员会的审查。
Moomoo Technologies Inc., Moomoo Financial Inc., Moomoo Financial Singapore Pte. Ltd., Futu Securities (Australia) Ltd, Moomoo Financial Canada Inc.,和Moomoo Securities Malaysia Sdn. Bhd.是关联公司。
- 分享到weixin
- 分享到qq
- 分享到facebook
- 分享到twitter
- 分享到微博
- 粘贴板
使用浏览器的分享功能，分享给你的好友吧